Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease (APEX-PD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
IMPAX Laboratories, Inc.
ClinicalTrials.gov Identifier:
NCT00880620
First received: April 3, 2009
Last updated: September 27, 2013
Last verified: September 2013

April 3, 2009
September 27, 2013
April 2009
October 2010   (final data collection date for primary outcome measure)
Unified Parkinson's Disease Rating Scale, parts I-IV [ Time Frame: Week 30 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00880620 on ClinicalTrials.gov Archive Site
  • Parkinson's Disease Questionnaire-39, Patient Global Impression, Clinical Global Impression [ Time Frame: Week 30 ] [ Designated as safety issue: No ]
  • Safety [ Time Frame: Week 30 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

This study examines the efficacy of IPX066 as compared to placebo in Parkinson's disease.

A randomized, placebo controlled, fixed dose, parallel arm study of three doses of IPX066 versus placebo.

Approximately 350 subjects are equally randomized to receive one of 3 doses of IPX066, or matching placebo, orally.

Study duration is approximately 30 weeks for each subject.

The UPDRS is the primary outcome measure.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Parkinson's Disease
  • Drug: placebo
    placebo
  • Drug: IPX066
    dose level 1
    Other Name: CD-LD ER
  • Drug: IPX066
    dose level 2
    Other Name: CD-LD ER
  • Drug: IPX066
    dose level 3
    Other Name: CD-LD ER
  • Placebo Comparator: 1
    Placebo
    Intervention: Drug: placebo
  • Experimental: 2
    IPX066 dose level 1
    Intervention: Drug: IPX066
  • Experimental: 3
    IPX066 dose level 2
    Intervention: Drug: IPX066
  • Experimental: 4
    IPX066 dose level 3
    Intervention: Drug: IPX066
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
381
November 2010
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Able to understand and willing to voluntarily sign an informed consent form (ICF) and Health Insurance Portability and Accountability Act (HIPAA) authorization or local equivalent if applicable.
  2. Diagnosed with idiopathic PD.
  3. LD-naïve: defined as subjects not exposed to LD or catechol-O-methyl transferase inhibitors for more than 30 days and the exposure is not within 4 weeks prior to study enrollment.
  4. If currently taking anticholinergic therapy, amantadine, or a monoamine oxidase type B (MAO-B) inhibitor, maintains a stable regimen for at least 4 weeks prior to Baseline, and agrees to maintain the stable regimen throughout study participation.
  5. Agrees to use a medically acceptable method of contraception throughout the study and for 1 month after completing the study.
  6. Able and willing to comply with the protocol, including availability for all scheduled clinic visits and telephone calls.

Exclusion Criteria:

  1. Pregnant or breastfeeding.
  2. Diagnosed with atypical Parkinsonism or any known secondary parkinsonian syndrome.
  3. Prior functional neurosurgical treatment for PD or if such procedures are anticipated during study participation.
  4. Use of nonselective MAO inhibitors.
  5. Use of dopamine agonists within 30 days prior to Screening.
  6. Unable to tolerate a placebo regimen, in the Investigator's opinion.
  7. Treatment of psychosis with any antipsychotic.
  8. History of seizure or epilepsy.
  9. Active or prior medical condition or prior surgical procedure that would interfere with LD absorption.
  10. History of narrow-angle glaucoma.
  11. Subjects with a history of malignant melanoma.
  12. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome.
  13. Received any investigational medications during the 30 days prior to Screening.
Both
30 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada,   Estonia,   Latvia,   Lithuania,   Romania,   Ukraine
 
NCT00880620
IPX066-B08-05
No
IMPAX Laboratories, Inc.
IMPAX Laboratories, Inc.
Not Provided
Study Director: Impax Study Director Impax Pharmaceuticals, a division of Impax Laboratories
IMPAX Laboratories, Inc.
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP